|
|
|
30.10.26 - 13:06
|
Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology (GlobeNewswire EN)
|
|
|
TUSTIN, Calif. and ST. LOUIS, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Canon Medical Systems USA, a leader in innovative diagnostic imaging solutions, and Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced a technology compatibility and commercial collaboration to pair Canon Medical's Alphenix interventional imaging platform with Stereotaxis' GenesisX Robotic Magnetic Navigation system....
|
|
|
|
|
|
|
30.10.26 - 07:12
|
HOYA Q2 Net Income Rises; Revenue Up 10.9% (AFX)
|
|
|
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - HOYA Corporation (HYB.F, 7741.T) reported second quarter profit attributable to owners of 70.7 billion yen, an increase of 27.6% from the prior year period. Di......
|
|
|
|
|
|
|
|
|
|
|
|
|
30.10.26 - 05:21
|
Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results (Business Wire)
|
|
|
Revenue increased 19.7% to 1.167 trillion yen year-over-year driven by Enhertu® and Datroway®
Fiscal year 2026 guidance for revenue and operating profit remains unchanged
Earnings call to take place on Friday, October 30 at 5:30 pm Japan Standard Time
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the second quarter of fiscal year 2026, ending September 30, 2026.
“Strong revenue growth continues in the second quarter of fiscal year 2026, driven by Enhertu and Datroway. These medicines have received nine new approvals across multiple indications since last quarter, including same day breast cancer approvals in Japan and China, which will allow us to bring these medicines to more patients,” said Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo. “We also continue to explore novel combination strategies to deliver greater benefits to more patients through our DXd antibody drug conjugates as demonstrated by our new clinical trial collaboration to evaluate Datrowa...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.10.26 - 12:24
|
Shionogi H1 Earnings Up 44%, Raises FY26 Outlook (AFX)
|
|
|
TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF), a Japanese drug manufacturing company, reported a 44 percent rise in profit for the first half of fiscal 2026 on higher revenues that grew 64.5 perc......
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
